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A B S T R A C T
Objectives: This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and
eﬃcacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carbo-
platin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).
Patients and methods: In this open-label, non-randomized study, patients with previously untreated ED-SCLC
received roniciclib twice daily (BID) in a 3 days on/4 days oﬀ schedule. Cisplatin 75 mg/m2 or carboplatin
(AUC5) dose was administered on day 1, and etoposide 100mg/m2 on days 1–3, of 21-day cycles. Phase Ib used
a dose-escalation design to deﬁne the MTD for phase II. Pharmacokinetics were assessed.
Results: Forty-three patients received treatment (roniciclib 2.5mg BID [+CARBO-ETOP, n= 4;+CIS-ETOP,
n= 3] and roniciclib 5mg BID [+CARBO-ETOP, n=24;+CIS-ETOP, n= 12]). The MTD of roniciclib was
5mg BID with CARBO-ETOP or CIS-ETOP. Common adverse events were nausea (90.7%) and vomiting (69.8%).
Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5–1 h), with a 30–40%
reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had
no eﬀect on etoposide or platinum pharmacokinetics. The response rate was 81.4% (35/43) overall and 86.1%
(31/36) in the pooled roniciclib 5 mg BID population (all partial responses).
Conclusion: Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability,
acceptable pharmacokinetics, and promising eﬃcacy. An observed safety signal in a related phase II study re-
sulted in discontinuation of the present study and termination of further roniciclib development.
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1. Introduction
Small-cell lung cancer (SCLC) aﬀects approximately 30,000 patients
yearly in the USA, with two-thirds of patients presenting with ex-
tensive-disease SCLC (ED-SCLC) [1–3]. SCLC is characterized by rapid
cellular growth and aggressive metastases, and patients with ED-SCLC
currently have no curative options and a median survival of about 10
months [4]. Platinum-based combination chemotherapy is the mainstay
of therapy for ED-SCLC, with cisplatin- or carboplatin-based che-
motherapy showing equivalent eﬃcacy in randomized studies [3–5].
Most cases initially show response to treatment; however, almost all
patients experience relapse and limited survival [6], emphasizing a
need for better treatment options.
In tumor cells, deregulation of the cell cycle arises through over-
expression or ampliﬁcation of cell-cycle activators including cyclin-
dependent kinases (CDKs; e.g. CDK4 and CDK6) and inactivation of cell-
cycle inhibitors (e.g. p16 and Rb) [7]. Non-cell-cycle CDKs (e.g. CDK7
and CDK9) contribute to transcription initiation via phosphorylation of
RNA polymerase II [7]. Inhibition of all CDKs leads to cell-cycle arrest
and down-regulation of anti-apoptotic proteins, resulting in an induc-
tion of apoptosis and inhibition of tumor cell proliferation [8]. There-
fore, CDK inhibitors are an attractive therapeutic target in cancer.
Roniciclib (Bayer AG, Leverkusen, Germany) is a novel, highly po-
tent, orally active, small-molecule pan-CDK inhibitor [9] that has de-
monstrated more than additive eﬃcacy in combination with cisplatin-
etoposide therapy (CIS-ETOP) in preclinical SCLC xenograft models,
without worsening toxicity [9]. In a phase I study of patients with ad-
vanced malignancies receiving single-agent roniciclib, the maximum
tolerated dose (MTD) was determined to be 7.5 mg twice daily (BID),
administered 3 days on/4 days oﬀ in a 21-day cycle, but the re-
commended phase II dose (RP2D) was reduced to 5mg BID because of
observed thromboembolic events [10]. An expansion cohort with ro-
niciclib monotherapy in pretreated SCLC patients at the RP2D demon-
strated an acceptable safety proﬁle and a moderate disease control rate
(DCR) of 17.4%, warranting further exploration as a treatment option
in patients with advanced SCLC [10].
Here we describe the results of a phase Ib/II study of roniciclib in
combination with CIS-ETOP or carboplatin-etoposide therapy (CARBO-
ETOP) as ﬁrst-line treatment in patients with ED-SCLC (NCT01573338).
2. Patients and methods
2.1. Study design
This open-label, non-randomized, multicenter study comprised two
phases. The primary objective of phase Ib was to evaluate the safety,
tolerability, pharmacokinetics (PK), and MTD of roniciclib in combi-
nation with CIS-ETOP or CARBO-ETOP in patients with ED-SCLC in two
parallel cohorts. Secondary objectives included biomarker response,
overall survival (OS), progression-free survival (PFS), response rate,
duration of response (DoR), stable disease, and DCR.
The primary objective of phase II was to evaluate the response rate
in patients with ED-SCLC receiving ﬁrst-line CIS-ETOP or CARBO-ETOP
in combination with roniciclib. The secondary objectives included tol-
erability, safety proﬁle, biomarker response proﬁle, OS, PFS, DoR,
stable disease, and DCR for roniciclib in combination with che-
motherapy and subsequent maintenance treatment with roniciclib.
2.2. Patients
Eligibility criteria included: aged ≥18 years with histologically or
cytologically conﬁrmed and previously untreated ED-SCLC; Eastern
Cooperative Oncology Group performance status of 0 or 1; life ex-
pectancy≥12 weeks; serum sodium≥130mmol/L; and adequate bone
marrow, liver, and renal functions. At least one solid tumor lesion
measurable according to Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 was required for inclusion in phase II.
Exclusion criteria included: any prior systemic anticancer therapy or
radiotherapy, or anticoagulation therapy; hepatic impairment of Child-
Pugh class B or C; a history of cardiac disease or organ allograft; human
immunodeﬁciency virus infection or chronic hepatitis B or C virus;
symptomatic metastatic brain or meningeal tumors; or previous or co-
existing cancer distinct in primary site or histology from the cancer
evaluated in this study (excluding cervical cancer in situ, treated basal
cell carcinoma, superﬁcial bladder tumors, or any cancer curatively
treated more than 3 years before study entry).
2.3. Treatment
Roniciclib was administered BID on a 3 days on/4 days oﬀ schedule
in 21-day cycles (Supplementary Table 1). In patients with PK assess-
ment, roniciclib was not administered on cycle 1, day 1, in order to
determine the PK proﬁle of chemotherapy without roniciclib. Cisplatin
75mg/m2 or carboplatin (dose determined by Calvert’s formula to yield
an area under the curve of 5mg/mL*min) was administered in-
travenously on day 1 of each cycle. Platinum agent was at the in-
vestigator’s discretion, and patients could switch treatments if they did
not tolerate speciﬁc toxicities. Etoposide 100mg/m2 was administered
intravenously on days 1–3 of each cycle. Chemotherapy continued for a
maximum of six cycles or until tumor progression, unacceptable toxi-
city, or withdrawal from the study. Dosing of roniciclib continued until
tumor progression, unacceptable toxicity, or study withdrawal.
In phase Ib, roniciclib was administered to three patients each at a
starting dose of 2.5mg BID in combination with CIS-ETOP or CARBO-
ETOP, i.e. one dose level below the RP2D of single-agent roniciclib 5mg
BID [10], in two parallel, independent cohorts. Dosing progressed in a
modiﬁed 3+3 dose-escalation/de-escalation design to a maximum
roniciclib dose of 5mg BID and a minimum dose of 2.5mg once daily. If
one of the three patients within a cohort at the starting dose experi-
enced a dose-limiting toxicity (DLT) during cycle 1, a further three
patients were enrolled to that cohort. A DLT was deﬁned as any of the
following occurring during cycle 1 and regarded to be related to roni-
ciclib or the combination of roniciclib with chemotherapy: absolute
neutrophil counts< 0.5× 109/L for≥7 days; febrile neutropenia with
absolute neutrophil counts< 0.5×109/L and fever ≥38.5 °C; any
grade 3–5 non-hematologic toxicity; or any grade 4 vomiting event or
grade 3 nausea or vomiting lasting over 48 h. If two or more of three or
two or more of six patients within a cohort experienced a DLT at the
starting dose, enrollment to that cohort was discontinued and dosing
was to be de-escalated to 2.5mg once daily.
If none of three or one of six patients in either cohort experienced a
DLT at the starting dose of roniciclib 2.5mg BID in combination with
chemotherapy, the roniciclib dose was escalated to 5mg BID for six
patients in each cohort. If one of six patients in each of the parallel
cohorts experienced a DLT, then 5mg BID was deﬁned as the MTD in
combination with chemotherapy; if two or more of three or two or more
of six patients experienced a DLT within a cohort, then enrollment was
to be discontinued. The tolerability of the starting dose of roniciclib
2.5 mg BID in combination with chemotherapy was then evaluated in
six patients, with 2.5mg BID deﬁned as the MTD if one or more of six
patients experienced a DLT.
The studies were conducted in accordance with the Declaration of
Helsinki. The protocol was approved by the ethics committee at each
participating center. All patients provided written, informed consent
before enrollment.
2.4. Assessments
PK assessments were conducted in all patients in phase Ib and were
planned in approximately six patients per chemotherapy regimen in
phase II. Plasma samples for PK assessments were collected as follows:
cycle 1, day 8 and cycle 2, day 1 at pre-dose, 0.5, 1, 2, 4, 6, and 8 h post-
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dose for roniciclib and its metabolite M-1; cycle 1, day 1 and cycle 2,
day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 h after start of
cisplatin or carboplatin infusion for total and free platinum; and cycle 1,
day 1 and cycle 2, day 1 at pre-dose, 0.5, 1, 2, 3, 4, 5, 7, and 24 h after
start of etoposide infusion for total etoposide. Plasma concentrations
were measured using validated analytical methods, and PK parameters
were calculated by non-compartmental analysis using WinNonlin®
software (Certara USA, Inc., Princeton, NJ).
Tumors were assessed by computed tomography or magnetic re-
sonance imaging using RECIST version 1.1 at baseline, then every two
cycles. Conﬁrmatory scans were performed ≥4 weeks following the
observation of a tumor response. For patients without disease pro-
gression, follow-up evaluation was done until death, if possible.
Patients treated at the MTD in phase Ib were included in the response
evaluation of phase II.
Safety was assessed throughout the treatment period and approxi-
mately 14 and 30 days after discontinuing roniciclib. Safety variables
included physical examinations, vital signs, concomitant medications,
and adverse events recorded using National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0.
2.5. Statistical analysis
Summary statistics were calculated for the total study population
and by cohort. Frequency tables were generated for qualitative data.
Statistical analysis was performed using SAS version 9.2 (SAS Institute
Inc., Cary, NC). All patients who received one or more doses of roni-
ciclib were included in the safety evaluation. Study sample size in phase
Ib was dependent on the number of dose-escalation/de-escalation steps
required for determination of the MTD. In phase II, a clinically mean-
ingful improvement was deﬁned as a 20% increase in response rate
from 60% to 80%. A total of 36 evaluable patients was determined to be
suﬃcient to detect a 20% diﬀerence in response rate with a signiﬁcance
level of 10% and power of 90%. Response rate was deﬁned as the
proportion of patients with a best tumor response of conﬁrmed partial
response or conﬁrmed complete response achieved during or within
30 days after treatment. DCR was deﬁned as the proportion of patients
with a best tumor response of complete response, partial response, or
stable disease during or within 30 days after treatment.
PK summary statistics were calculated for each sampling point.
Means were calculated if at least two-thirds of the individual data were
measured and were above the lower limit of quantiﬁcation. For calcu-
lation of the mean value, a data point below the lower limit of quan-
tiﬁcation was substituted by one-half the lower limit. Individual and
geometric mean concentration–time curves of roniciclib and its meta-
bolite M-1, total and free platinum, and total etoposide (using the ac-
tual sampling times for individual plots and the planned sampling times
for mean plots) were plotted by treatment.
PK parameters were calculated for total and free platinum, etopo-
side, and roniciclib and its metabolite M-1. To investigate PK interac-
tion, an explorative analysis of variation was performed on the log-
transformed values of PK parameters.
3. Results
3.1. Patient disposition, demographics, and baseline characteristics
In total, 58 patients were enrolled and 43 patients were eligible to
receive treatment across four cohorts (roniciclib 2.5mg BID [+CARBO-
ETOP, n= 4;+CIS-ETOP, n= 3] and roniciclib 5mg BID [+CARBO-
ETOP, n=24;+CIS-ETOP, n=12]) (Table 1). Seven patients were
enrolled to phase Ib. No DLTs were reported at the starting dose of
roniciclib 2.5mg BID; therefore, the dose was escalated to 5mg BID.
Thirty-six patients were enrolled to phase II; 12 patients were treated
with roniciclib 5mg BID+CIS-ETOP and 24 patients with roniciclib
5mg BID+CARBO-ETOP. Five of the 12 patients receiving roniciclib
5mg BID+CIS-ETOP switched to treatment with CARBO-ETOP during
the study at the investigator’s decision. Per protocol, these patients
were considered part of the CIS-ETOP cohort for analyses. All patients
assigned to treatment comprised the safety analysis set. Eighteen pa-
tients were valid for PK analysis. The primary reason for discontinua-
tion was radiologic progression (62.8%).
Of the patients treated, 29 (67.4%) were male, median age was 60
years (range 43–76), and 26 (60.5%) had an Eastern Cooperative
Oncology Group performance status of 1 (Table 1). Three patients
(7.0%) had received any prior anticancer therapeutic procedure, while
concurrent therapy included anticancer therapeutic procedures (six
patients [14.0%]), radiotherapy (nine patients [20.9%]), and diagnostic
procedures (four patients [9.3%]) (Table 1).
3.2. Exposure and dose escalation
The overall median duration of treatment was 23.6 weeks (range
2.4–142.4) and patients received a median of eight cycles (range 2–47),
with roniciclib monotherapy continuing after a maximum of six che-
motherapy cycles (Table 2). Most patients (62.8%) received treatment
for 20–40 weeks. Twenty-ﬁve patients (89.3%) in the ronici-
clib+CARBO-ETOP cohorts received six cycles of chemotherapy,
compared with only seven patients (46.7%) in the roniciclib+ CIS-
ETOP cohorts. Median treatment duration and median number of
treatment cycles were comparable across dose levels and combinations
(Table 2).
One patient receiving roniciclib 5mg BID+CARBO-ETOP experi-
enced hypokalemia and hypocalcemia, both reported as DLTs and as-
sessed as related to roniciclib, carboplatin, and etoposide. One patient
receiving roniciclib 5mg BID+CIS-ETOP experienced hypotension,
neutropenia, sepsis, febrile neutropenia, and decreased platelet count,
all reported as DLTs and assessed as related to roniciclib, carboplatin,
and etoposide. The roniciclib MTD was determined to be 5mg BID
administered 3 days on/4 days oﬀ in combination with CARBO-ETOP or
CIS-ETOP and was the dose used for phase II.
3.3. Safety
At least one treatment-related adverse event (TEAE) was reported in
all patients (100%); frequencies were generally similar across dose le-
vels and combinations (Table 3). The most common TEAEs of any grade
were nausea (90.7%), vomiting (69.8%), and anemia, decreased neu-
trophil count, and decreased platelet count (67.4% each) (Table 3).
Standard anti-emetic therapy was used to manage nausea and vomiting.
TEAEs of worst grade 3 were reported in 16 patients (37.2%), most
commonly anemia (27.9%), hypomagnesemia and decreased white
blood cell count (18.6% each), decreased neutrophil count (16.3%),
and decreased platelet count (11.6%). TEAEs of worst grade 4 were
reported in 22 patients (51.2%), most commonly decreased neutrophil
count (39.5%), decreased platelet count (27.9%), and sepsis (4.7%).
Grade 5 TEAEs occurred in two patients (4.7%) receiving roniciclib
5mg BID; one with lung infection (associated with disease progression)
and the other with hypercarbic respiratory failure (not associated with
disease progression). One additional patient died within 30 days after
treatment with roniciclib 5mg BID+CIS-ETOP (associated with dis-
ease progression), but no adverse event was reported as associated with
the death so no grade 5 event was reported. No deaths were assessed as
roniciclib-related.
Roniciclib-related TEAEs were experienced by 42 patients (97.7%),
most commonly nausea (88.4%) and vomiting (67.4%) (Supplementary
Table 2). Worst grade 3 roniciclib-related TEAEs were experienced by
12 patients (27.9%), most commonly anemia and decreased white
blood cell count (18.6% each), decreased neutrophil count (16.3%),
and decreased platelet count and hypomagnesemia (11.6% each), and
worst grade 4 roniciclib-related TEAEs were experienced by 16 patients
(37.2%), most commonly decreased neutrophil count (27.9%) and
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decreased platelet count (20.9%).
Twenty-one patients (48.8%) experienced serious adverse events
(Table 3). Serious adverse events reported in one or more patients in-
cluded lung infection (4/43; 9.3%) and febrile neutropenia, decreased
neutrophil count, decreased platelet count, sepsis, and vascular dis-
orders (other) (2/43 each; 4.7%). The majority of serious adverse
events were of worst grade 3 (23.3%) (Table 3). Serious adverse events
were assessed as roniciclib-related in seven patients (16.3%): febrile
neutropenia, decreased neutrophil count, and decreased platelet count
(2/43 each; 4.7%), and fatigue, hyponatremia, hypotension, nausea,
maculo-papular rash, sepsis, syncope, and vomiting (1/43 each; 2.3%).
Twenty-nine patients (67.4%) had one or more dose modiﬁcations
of roniciclib (reduction or interruption) during the ﬁrst six treatment
cycles in combination with chemotherapy. TEAEs leading to dose
modiﬁcation were reported in 28 patients (65.1%) (Table 3); events
were considered roniciclib-related in 23 patients (53.5%) (Supple-
mentary Table 2). TEAEs led to permanent discontinuation of roniciclib
in ﬁve patients (11.6%) (Table 3), in whom one event (2.3%) was
considered roniciclib-related (Supplementary Table 2). Nine patients
(20.9%) received whole-brain radiotherapy; dosing of roniciclib was
interrupted during this period. Dose modiﬁcations were reported in 23
patients (65.1%) for carboplatin, six patients (14.0%) for cisplatin, and
30 patients (69.8%) for etoposide.
3.4. Pharmacokinetics
Roniciclib geometric mean plasma concentration–time proﬁles are
shown in Figs. 1A and B. Following administration of roniciclib 5mg
alone, roniciclib was rapidly absorbed with median time to maximum
drug concentration values of 0.5 and 0.75 h and displayed slightly de-
layed absorption when co-administered with CARBO-ETOP (Fig. 1).
After administration of roniciclib 5mg alone and co-administered with
chemotherapy, mean plasma concentrations of the M-1 metabolite
showed no signiﬁcant change over 8 h. Mean plasma concentrations of
M-1 were in the range of approximately 0.2–0.5 μg/L and 0.2–0.8 μg/L
after administration of roniciclib 5mg alone and when co-administered
with CARBO-ETOP or CIS-ETOP therapy, respectively (data not shown).
Similar PK characteristics were observed with roniciclib 2.5mg (data
not shown). PK parameters for roniciclib and roniciclib metabolite M-1
in plasma following administration of roniciclib 2.5 mg and 5mg alone
and with CIS-ETOP and CARBO-ETOP are shown in Supplementary
Table 3.
When roniciclib 5mg was co-administered with CARBO-ETOP or
CIS-ETOP, no changes were observed in the geometric mean con-
centration–time proﬁles of free platinum, total platinum, or etoposide,
as shown in Supplementary Fig. 1.
Roniciclib exposure was approximately 30–40% lower when co-
administered with CARBO-ETOP or CIS-ETOP compared with roniciclib
alone (Supplementary Table 3). Etoposide, free platinum, and total
platinum concentrations were ≤20% diﬀerent on average between
cycles 1 and 2, indicating no clinically relevant eﬀect of concomitant
administration of roniciclib on etoposide or free platinum and total
platinum PK parameters (Supplementary Fig. 1).
3.5. Eﬃcacy
All patients who received treatment were evaluable for eﬃcacy.
Overall, no patient achieved a conﬁrmed complete response and 35
Table 1
Demographics and baseline characteristics (safety analysis set).
Roniciclib 2.5 mg BID Roniciclib 5mg BID Total (N=43)
CARBO-ETOP (n=4) CIS-ETOP (n=3) CARBO-ETOP (n= 24) CIS-ETOP (n=12)
Male, n (%) 2 (50.0) 1 (33.3) 19 (79.2) 7 (58.3) 29 (67.4)
Median age, years (range) 71.5 (56–73) 58.0 (55–65) 60.5 (48–76) 59.5 (43–75) 60.0 (43–76)
Baseline ECOG PS, n (%)
0 3 (75.0) 2 (66.7) 7 (29.2) 4 (33.3)a 16 (37.2)a
1 1 (25.0) 1 (33.3) 17 (70.8) 7 (58.3) 26 (60.5)
Median time since initial diagnosis, weeks (range) 3.6 (1–5) 3.7 (2–4) 2.1 (1–9) 2.8 (1–4) 2.6 (1–9)
Any prior anticancer therapeutic procedure, n (%) 0 1 (33.3) 1 (4.2) 1 (8.3) 3 (7.0)
Concurrent anticancer therapies, n (%)
Any therapeutic procedure 1 (25.0) 2 (66.7) 2 (8.3) 1 (8.3) 6 (14.0)
Any radiotherapy 1 (25.0) 0 3 (12.5) 5 (41.7) 9 (20.9)
Any diagnostic procedure 0 0 2 (8.3) 2 (16.7) 4 (9.3)
Number of target lesions, n (%)
1 1 (25.0) 0 5 (20.8) 0 6 (14.0)
2 2 (50.0) 1 (33.3) 6 (25.0) 1 (8.3) 10 (23.3)
≥3 1 (25.0) 2 (66.7) 13 (54.2) 11 (91.7) 27 (62.8)
Number of non-target lesions, n (%)
0 0 0 3 (12.5) 2 (16.7) 5 (11.6)
1 0 1 (33.3) 5 (20.8) 2 (16.7) 8 (18.6)
2 1 (25.0) 0 8 (33.3) 2 (16.7) 11 (25.6)
≥3 3 (75.0) 2 (66.7) 8 (33.3) 6 (50.0) 19 (44.2)
BID= twice daily; CARBO-ETOP= carboplatin-etoposide therapy; CIS-ETOP= cisplatin-etoposide therapy; ECOG PS=Eastern Cooperative Oncology Group per-
formance status.
a Value missing for one patient.
Table 2
Roniciclib duration of treatment (safety analysis set).
Roniciclib 2.5 mg BID Roniciclib 5mg BID Total (N=43)
CARBO-ETOP (n= 4) CIS-ETOP (n= 3) CARBO-ETOP (n= 24) CIS-ETOP (n= 12)
Median duration of treatment, weeks (range) 25.0 (18.3–34.7) 23.6 (3.4–142.4) 24.7 (3.0–49.6) 21.7 (2.4–35.3) 23.6 (2.4–142.4)
Median number of cycles (range) 8.5 (6.0–12.0) 8.0 (2.0–47.0) 8.0 (2.0–14.0) 8.0 (2.0–12.0) 8.0 (2.0–47.0)
BID= twice daily; CARBO-ETOP= carboplatin-etoposide therapy; CIS-ETOP= cisplatin-etoposide therapy.
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Table 3
Summary of safety and incidence of treatment-emergent adverse events (by worst CTCAE grade) occurring in ≥10% of patients (safety analysis set).
n (%) Roniciclib 2.5 mg BID Roniciclib 5mg BID Total
(N=43)
CARBO-ETOP
(n= 4)
CIS-ETOP
(n=3)
CARBO-ETOP
(n=24)
CIS-ETOP
(n= 12)
Any TEAEa 4 (100) 3 (100) 24 (100) 12 (100) 43 (100)
Worst grade
1 0 1 (33.3) 0 0 1 (2.3)
2 0 0 2 (8.3) 0 2 (4.7)
3 1 (25.0) 1 (33.3) 7 (29.2) 7 (58.3) 16 (37.2)
4 3 (75.0) 1 (33.3) 13 (54.2) 5 (41.7) 22 (51.2)
5 (death) 0 0 2 (8.3) 0b 2 (4.7)b
Serious adverse events 0 2 (66.7) 13 (54.2) 6 (50.0) 21 (48.8)
Worst grade
1 0 0 0 0 0
2 0 0 2 (8.3) 2 (16.7) 4 (9.3)
3 0 2 (66.7) 5 (20.8) 3 (25.0) 10 (23.3)
4 0 0 4 (16.7) 1 (8.3) 5 (11.6)
5 (death) 0 0 2 (8.3) 0b 2 (4.7)b
Patients with TEAEs leading to dose
modiﬁcationc
3 (75.0) 1 (33.3) 18 (75.0) 6 (50.0) 28 (65.1)
Patients with TEAEs leading to
permanent discontinuation of
study drug
1 (25.0) 0 3 (12.5) 1 (8.3) 5 (11.6)
Incidence of TEAEs (any grade) occurring in ≥10% of the total population
Nausea 3 (75.0) 2 (66.7) 23 (95.8) 11 (91.7) 39 (90.7)
Vomiting 4 (100) 1 (33.3) 15 (62.5) 10 (83.3) 30 (69.8)
Anemia 4 (100) 2 (66.7) 15 (62.5) 8 (66.7) 29 (67.4)
Decreased neutrophil count 3 (75.0) 2 (66.7) 17 (70.8) 7 (58.3) 29 (67.4)
Decreased platelet count 4 (100) 1 (33.3) 18 (75.0) 6 (50.0) 29 (67.4)
Diarrhea 3 (75.0) 1 (33.3) 14 (58.3) 10 (83.3) 28 (65.1)
Anorexia 1 (25.0) 2 (66.7) 10 (41.7) 11 (91.7) 24 (55.8)
Alopecia 4 (100) 2 (66.7) 12 (50.0) 6 (50.0) 24 (55.8)
Fatigue 2 (50.0) 2 (66.7) 10 (41.7) 8 (66.7) 22 (51.2)
Headache 1 (25.0) 0 12 (50.0) 6 (50.0) 19 (44.2)
Hypomagnesemia 1 (25.0) 1 (33.3) 7 (29.2) 7 (58.3) 16 (37.2)
Decreased white blood cell count 2 (50.0) 1 (33.3) 8 (33.3) 4 (33.3) 15 (34.9)
Constipation 1 (25.0) 0 7 (29.2) 5 (41.7) 13 (30.2)
Dizziness 2 (50.0) 2 (66.7) 3 (12.5) 5 (41.7) 12 (27.9)
Hypokalemia 1 (25.0) 1 (33.3) 7 (29.2) 2 (16.7) 11 (25.6)
Hyponatremia 1 (25.0) 1 (33.3) 6 (25.0) 3 (25.0) 11 (25.6)
Insomnia 0 1 (33.3) 6 (25.0) 4 (33.3) 11 (25.6)
Cough 1 (25.0) 1 (33.3) 5 (20.8) 4 (33.3) 11 (25.6)
Limb edema 1 (25.0) 0 4 (16.7) 4 (33.3) 9 (20.9)
Upper respiratory infection 0 0 7 (29.2) 2 (16.7) 9 (20.9)
Dyspnea 0 0 6 (25.0) 3 (25.0) 9 (20.9)
Pain 0 2 (66.7) 5 (20.8) 1 (8.3) 8 (18.6)
Myalgia 0 1 (33.3) 5 (20.8) 2 (16.7) 8 (18.6)
Tinnitus 1 (25.0) 1 (33.3) 0 5 (41.7) 7 (16.3)
Increased alanine aminotransferase 1 (25.0) 1 (33.3) 3 (12.5) 2 (16.7) 7 (16.3)
Generalized muscle weakness 0 0 3 (12.5) 4 (33.3) 7 (16.3)
Fever 0 0 4 (16.7) 2 (16.7) 6 (14.0)
Lung infection 0 0 5 (20.8) 1 (8.3) 6 (14.0)
Urinary tract infection 0 1 (33.3) 3 (12.5) 2 (16.7) 6 (14.0)
Gastrointestinal disorders – other 1 (25.0) 1 (33.3) 1 (4.2) 2 (16.7) 5 (11.6)
General disorders and
administration site conditions –
other
1 (25.0) 1 (33.3) 2 (8.3) 1 (8.3) 5 (11.6)
Infective rhinitis 1 (25.0) 0 0 4 (33.3) 5 (11.6)
Increased aspartate
aminotransferase
1 (25.0) 1 (33.3) 2 (8.3) 1 (8.3) 5 (11.6)
Hyperglycemia 1 (25.0) 0 2 (8.3) 2 (16.7) 5 (11.6)
Hypoalbuminemia 0 1 (33.3) 3 (12.5) 1 (8.3) 5 (11.6)
Hypocalcemia 0 1 (33.3) 2 (8.3) 2 (16.7) 5 (11.6)
Dysgeusia 1 (25.0) 0 0 4 (33.3) 5 (11.6)
Hypertension 0 1 (33.3) 1 (4.2) 3 (25.0) 5 (11.6)
BID= twice daily; CARBO-ETOP= carboplatin-etoposide therapy; CIS-ETOP= cisplatin-etoposide therapy; CTCAE=Common Terminology Criteria for Adverse
Events version 4.0; TEAE= treatment-emergent adverse event.
a Number (%) of patients with the speciﬁed event starting or worsening between the start of treatment and 30 days after the end of treatment.
b In the roniciclib 5mg BID+CIS-ETOP cohort, one patient died within 30 days after treatment but did not have a reported adverse event that was associated with
the death; therefore, there is no grade 5 event representing this death.
c Dose modiﬁcations included delays, interruptions, and reductions.
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patients (81.4%) achieved a conﬁrmed partial response, resulting in a
response rate of 81.4% (Table 4). Five patients (11.6%) had stable
disease, two patients (4.7%) had disease progression, and one patient
(2.3%) had a missing evaluation (Table 4). The response rate was si-
milar in the pooled roniciclib 5mg BID population (86.1%; n=31)
(Table 4). The DCR was 93.0% in the overall population and 94.4% in
the pooled roniciclib 5mg BID population (Table 4).
Median OS was 12.6 months overall (95% conﬁdence interval [CI]
9.8–17.2) and 13.4 months (95% CI 9.6–8.2) in the pooled roniciclib
5mg BID population, with little diﬀerence between the chemotherapy
groups: CARBO-ETOP, 14.1 months; CIS-ETOP, 11.2 months. Median
PFS was 6.7 months overall and in the pooled roniciclib 5mg BID po-
pulation (95% CI 5.5–7.6), and was 7.2 and 6.2 months for roniciclib
5mg BID with CARBO-ETOP or CIS-ETOP, respectively. Median time to
progression was 6.7 months (95% CI 5.4–7.6) in both the overall popu-
lation and the pooled roniciclib 5mg BID population (CARBO-ETOP, 7.5
months; CIS-ETOP, 5.7 months). Median DoR was 5.6 months overall
(95% CI 4.3–6.4) and 5.8 months (95% CI 4.3–7.0) in the pooled roni-
ciclib 5mg BID population (6.3 and 5.1 months for CARBO-ETOP or CIS-
ETOP, respectively). For the roniciclib 2.5mg BID CARBO-ETOP and CIS-
ETOP groups, median OS was 12.6 and 11.4 months, respectively;
median PFS and median time to progression were 6.7 and 5.4 months,
respectively, and median DoR was 5.6 and 4.2 months, respectively.
Given the very limited number of tissue samples available, the ex-
ploratory biomarker analysis was not pursued due to the insuﬃcient
clinical signiﬁcance expected.
4. Discussion
This phase Ib/II study evaluated the safety, PK, MTD, and eﬃcacy of
roniciclib in combination with platinum-based chemotherapy in pa-
tients with ED-SCLC. The MTD was roniciclib 5mg BID administered
orally in a 3 days on/4 days oﬀ regimen in combination with standard
CARBO-ETOP or CIS-ETOP, consistent with the RP2D for roniciclib
monotherapy reported in the ﬁrst-in-human phase I study [10]. Overall,
roniciclib was tolerated in combination with chemotherapy in patients
with ED-SCLC.
The most frequently observed TEAEs of any grade across all cohorts
were nausea, vomiting, anemia, decreased neutrophil count, and de-
creased platelet count, while the most common roniciclib-related TEAEs
were nausea and vomiting. In general, TEAEs were as anticipated given
the underlying poor condition of patients and the TEAEs expected for
roniciclib (nausea, fatigue, diarrhea, and vomiting) [10] and for pla-
tinum-based chemotherapy (anemia, neutropenia, thrombocytopenia,
and leukopenia) [11]. The frequencies of TEAEs were generally similar
across cohorts; however, comparisons should be made with caution
because of the small sample size of the roniciclib 2.5mg BID cohorts.
Serious adverse events were reported in 21 patients, most of which
correspond to those typically reported in an SCLC population treated
with chemotherapy, including hepatotoxicity, infections, and re-
spiratory failure [12,13]. Three deaths (lung infection, respiratory
failure, and unknown cause) were reported during this study. Pul-
monary events are common in the treated patient population and the
Fig. 1. Geometric mean plasma concentration–time proﬁles for roniciclib after
oral administration of roniciclib 5 mg BID alone and after co-administration
with CARBO-ETOP (A) and after oral administration of roniciclib 5 mg BID
alone and after co-administration with CIS-ETOP (B). Pharmacokinetic analysis
set. BID= twice daily; CARBO-ETOP= carboplatin-etoposide therapy; CIS-
ETOP= cisplatin-etoposide therapy.
Table 4
Response evaluation according to RECIST version 1.1 (safety analysis set).
n (%) Roniciclib 2.5mg BID Roniciclib 5mg BID Total (N=43)
CARBO-ETOP (n=4) CIS-ETOP (n= 3) CARBO-ETOP (n= 24) CIS-ETOP (n=12) Pooled roniciclib 5mg BID (n= 36)
Best overall response
Partial response 3 (75.0) 1 (33.3) 21 (87.5) 10 (83.3) 31 (86.1) 35 (81.4)
Stable disease 1 (25.0) 1 (33.3) 2 (8.3) 1 (8.3) 3 (8.3) 5 (11.6)
Disease progression 0 1 (33.3) 0 1 (8.3) 1 (2.8) 2 (4.7)
Missing 0 0 1 (4.2)a 0 1 (2.8) 1 (2.3)
Objective tumor response rate 3 (75.0) 1 (33.3) 21 (87.5) 10 (83.3) 31 (86.1) 35 (81.4)
Disease control rate 4 (100) 2 (66.7) 23 (95.8) 11 (91.7) 34 (94.4) 40 (93.0)
BID= twice daily; CARBO-ETOP= carboplatin-etoposide therapy; CIS-ETOP= cisplatin-etoposide therapy; RECIST=Response Evaluation Criteria in Solid
Tumors.
a Death caused by hypercarbic respiratory failure occurred after one cycle of treatment but before the cycle 2 response assessment.
B.C. Cho et al. Lung Cancer 123 (2018) 14–21
19
deaths were assessed as unrelated to roniciclib.
No clinically relevant PK interaction was observed upon con-
comitant administration of roniciclib and CARBO-ETOP or CIS-ETOP.
Exposures of etoposide, total platinum, and free platinum were not
aﬀected; however, roniciclib exposure (maximum drug concentration
and area under the curve) was observed to be lower when administered
with CARBO-ETOP or CIS-ETOP compared with administration as a
single agent. As there is no known mechanistic basis for PK interaction,
lower roniciclib exposure may be attributed, in part, to limited ab-
sorption as a result of increased gastrointestinal adverse events ob-
served after repeated administration of roniciclib.
Eﬃcacy results were promising in this study; 81.4% of patients
achieved a conﬁrmed partial response and 11.6% of patients achieved
stable disease. The overall response rate was 81.4%, with a response
rate of 86.1% at the MTD of roniciclib 5mg. These results are consistent
with response rates typically seen with standard chemotherapy in pa-
tients with ED-SCLC (70–85%) [14]. At the roniciclib MTD, median OS
was 13.4 months, median PFS was 6.7 months, median time to pro-
gression was 6.7 months, and median DoR was 5.8 months. The OS of
approximately 13 months was similar to previously reported treatment
strategies in ED-SCLC [14]. Response rates were also similar between
CARBO-ETOP and CIS-ETOP for patients receiving roniciclib 5mg BID
(87.5% and 83.3%, respectively). A meta-analysis comparing the eﬃ-
cacy of cisplatin versus carboplatin as ﬁrst-line treatment of SCLC also
demonstrated comparable response; median OS of 9.6 months and 9.4
months, median PFS of 5.5 and 5.3 months, and response rates of 67.1%
and 66.0% for cisplatin and carboplatin, respectively [5].
While our eﬃcacy data appear favorable, these data should be in-
terpreted with caution, particularly results with roniciclib 2.5mg BID
plus chemotherapy, for which patient numbers are too low to provide
meaningful clinical interpretation. In this study, no complete responses
were observed, contrasting with previous studies of standard che-
motherapy [14,15]. However, in 46.5% of patients receiving ronici-
clib+ CARBO-ETOP or CIS-ETOP, the dose of etoposide had to be re-
duced because of adverse events, potentially aﬀecting anti-tumor
response [15]. Overall, the sample size in this study was too small for
deﬁnite conclusions regarding eﬃcacy.
The chemotherapy regimens in this study are commonly used and
have been widely accepted for more than four decades [16–18], al-
though median survival for patients with ED-SCLC remains low, with
virtually every patient relapsing following response [14]. Thus far, the
addition of thalidomide, bevacizumab, pemetrexed, and oblimersen to
ﬁrst-line chemotherapy treatment in patients with ED-SCLC has re-
sulted in negative phase II and III studies [19]. Promising in vivo tumor
growth inhibition with roniciclib in combination with cisplatin and/or
etoposide in SCLC tumor models [9], coupled with an acceptable safety
proﬁle and moderate DCR in a phase I study of roniciclib monotherapy
[10], suggested a potential for roniciclib to improve ﬁrst-line treatment
outcomes in patients with ED-SCLC in combination with standard
chemotherapy.
In this study, the addition of roniciclib to standard chemotherapy
for the treatment of ED-SCLC showed a safety proﬁle similar to that
seen previously for roniciclib and for the chemotherapy combinations,
and no new safety signals were identiﬁed. Although occurrences of
thromboembolic events resulted in a reduction of the RP2D in the ﬁrst-
in-human study [10], only two patients (4.7%) experienced throm-
boembolic events with the combination of roniciclib with che-
motherapy. No clinically relevant PK interactions were observed, and
eﬃcacy results were potentially promising with a response rate of
81.4%. Nevertheless, when one patient on the present study had been
stable for over 40 cycles and was still receiving treatment with ronici-
clib 2.5 mg BID, a safety signal was observed in a related phase II,
placebo-controlled study evaluating the eﬃcacy and safety of roniciclib
in combination with CARBO-ETOP or CIS-ETOP as ﬁrst-line therapy in
patients with ED-SCLC (NCT02161419). Preliminary safety and eﬃcacy
data from that phase II study demonstrated an unfavorable beneﬁt/risk
balance for patients receiving roniciclib in combination with CARBO-
ETOP or CIS-ETOP [20]. As a result, treatment with roniciclib in the
present study was discontinued and further clinical development has
been terminated.
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